All AbMole products are for research use only, cannot be used for human consumption.
Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane.
Epidural administration of Ropivacaine hydrochloride monohydrate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine hydrochloride monohydrate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
 |
Source | Bioanalysis (2014). Figure 2. Ropivacaine hydrochloride |
| Method | cell culture | |
| Cell Lines | primary murine skeletal muscle cells | |
| Concentrations | 1.7 mM, 3.3 mM, 5.8 mM, 8.3 mM, 16.5 mM | |
| Incubation Time | 24 h | |
| Results | Treatment of myocytes with bupivacaine and ropivacaine in vitro leads to cell destruction in a doseand drug-dependent manner. |
| Cell Experiment | |
|---|---|
| Cell lines | C2C12 cell |
| Preparation method | The other part was treated with ropivacaine hydrochloride in the same concentrations (1.7 mM, 3.3 mM, 5.8 mM, 8.3 mM, 16.5 mM, respectively). After incubation for 1 and 2 hours, the LA was removed. |
| Concentrations | 1.7 mM, 3.3 mM, 5.8 mM, 8.3 mM, 16.5 mM |
| Incubation time | 1 or 2 h |
| Animal Experiment | |
|---|---|
| Animal models | Sprague-Dawley rats |
| Formulation | |
| Dosages | 0.12 ml/kg |
| Administration | i.v. |
| Molecular Weight | 328.88 |
| Formula | C17H28N2O2.HCl |
| CAS Number | 132112-35-7 |
| Solubility (25°C) | DMSO 68 mg/mL Water 40 mg/mL |
| Storage | -20°C, dry, sealed |
| Related Animal experimental anesthetics Products |
|---|
| Articaine hydrochloride
Articaine hydrochloride is a dental local anesthetic which contains an additional ester group that is metabolized by estearases in blood and tissue. Articaine hydrochloride ameliorates LPS-induced acute kidney injury via inhibition of NF-ĸB activation and the NLRP3 inflammasome pathway. |
| Benzocaine
Benzocaine is the ethyl ester of p-aminobenzoic acid (PABA), it is a local anesthetic commonly used for the research of topical pain reliever or in cough drops. Benzocaine shares a common receptor with all othe rLAs in the voltage-gated Na+ channel, with an IC50 of 0.8 mM tested with a potential of +30 mV. |
| Butacaine
Butacaine is a reversible nerve conduction blocker. Butacaine acts on the nervous system and nerve fibers, can cause both sensory and motor paralysis. Butacaine inhibits mouse heart MAO (type B) and rat heart MAO (type A) with IC50 of 62 μM and 400 μM, respectively. |
| Dibucaine hydrochloride
Dibucaine (Cinchocaine) hydrochloride is a sodium channel inhibitor. Dibucaine hydrochloride is a potent SChE inhibitor. Dibucaine hydrochloride is a local anesthetics. |
| Levobupivacaine hydrochloride
Levobupivacaine hydrochloride is a long-acting amide local anaesthetic. Levobupivacaine hydrochloride exerts anaesthetic and analgesic effects through reversible blockade of neuronal sodium channel. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
